Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.
